Literature DB >> 35723626

IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma.

Turan Aghayev1, Aleksandra M Mazitova1,2, Jennifer R Fang3, Sergei I Grivennikov2,4, Ekaterina K Koltsova1,2, Iuliia O Peshkova1, Matthew Rausch5, Manhsin Hung6,7, Kerry F White5, Ricard Masia5, Elizaveta K Titerina1, Aliia R Fatkhullina1, Isabelle Cousineau8, Simon Turcotte8, Dmitry Zhigarev1, Anastasiia Marchenko2, Svetlana Khoziainova2, Petr Makhov9, Yin Fei Tan10, Andrew V Kossenkov11, David L Wiest1, John Stagg8, Xin Wei Wang6,7, Kerry S Campbell1, Amiran K Dzutsev3, Giorgio Trinchieri3, Jonathan A Hill5.   

Abstract

Although inflammatory mechanisms driving hepatocellular carcinoma (HCC) have been proposed, the regulators of anticancer immunity in HCC remain poorly understood. We found that IL27 receptor (IL27R) signaling promotes HCC development in vivo. High IL27EBI3 cytokine or IL27RA expression correlated with poor prognosis for patients with HCC. Loss of IL27R suppressed HCC in vivo in two different models of hepatocarcinogenesis. Mechanistically, IL27R sig-naling within the tumor microenvironment restrains the cytotoxicity of innate cytotoxic lymphocytes. IL27R ablation enhanced their accumulation and activation, whereas depletion or functional impairment of innate cytotoxic cells abrogated the effect of IL27R disruption. Pharmacologic neutralization of IL27 signaling increased infiltration of innate cytotoxic lymphocytes with upregulated cytotoxic molecules and reduced HCC development. Our data reveal an unexpected role of IL27R signaling as an immunologic checkpoint regulating innate cytotoxic lymphocytes and promoting HCC of different etiologies, thus indicating a therapeutic potential for IL27 pathway blockade in HCC. SIGNIFICANCE: HCC, the most common form of liver cancer, is characterized by a poor survival rate and limited treatment options. The discovery of a novel IL27-dependent mechanism controlling anticancer cytotoxic immune response will pave the road for new treatment options for this devastating disease. This article is highlighted in the In This Issue feature, p. 1825. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35723626      PMCID: PMC9357073          DOI: 10.1158/2159-8290.CD-20-1628

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  112 in total

Review 1.  The immunobiology of interleukin-27.

Authors:  Hiroki Yoshida; Christopher A Hunter
Journal:  Annu Rev Immunol       Date:  2015       Impact factor: 28.527

2.  Effector differentiation downstream of lineage commitment in ILC1s is driven by Hobit across tissues.

Authors:  Christin Friedrich; Renske L R E Taggenbrock; Rémi Doucet-Ladevèze; Gosia Golda; Rebekka Moenius; Panagiota Arampatzi; Natasja A M Kragten; Katharina Kreymborg; Mercedes Gomez de Agüero; Wolfgang Kastenmüller; Antoine-Emmanuel Saliba; Dominic Grün; Klaas P J M van Gisbergen; Georg Gasteiger
Journal:  Nat Immunol       Date:  2021-08-30       Impact factor: 25.606

3.  Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.

Authors:  Denada Dibra; Abhisek Mitra; Melisa Newman; Xueqing Xia; Jeffry J Cutrera; Mihai Gagea; Eugenie S Kleinerman; Guillermina Lozano; Shulin Li
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

4.  Hepatic IL-17 responses in human and murine primary biliary cirrhosis.

Authors:  Ruth Y Z Lan; Thucydides L Salunga; Koichi Tsuneyama; Zhe-Xiong Lian; Guo-Xiang Yang; Willy Hsu; Yuki Moritoki; Aftab A Ansari; Claudia Kemper; Jeff Price; John P Atkinson; Ross L Coppel; M Eric Gershwin
Journal:  J Autoimmun       Date:  2008-12-19       Impact factor: 7.094

Review 5.  Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis.

Authors:  Hayato Nakagawa
Journal:  World J Hepatol       Date:  2015-08-18

6.  Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice.

Authors:  Tetsuaki Hirase; Hiromitsu Hara; Yoshiyuki Miyazaki; Noriko Ide; Ai Nishimoto-Hazuku; Hirokazu Fujimoto; Christiaan J M Saris; Hiroki Yoshida; Koichi Node
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-31       Impact factor: 4.733

Review 7.  NK cell self tolerance, responsiveness and missing self recognition.

Authors:  Nataliya Shifrin; David H Raulet; Michele Ardolino
Journal:  Semin Immunol       Date:  2014-03-12       Impact factor: 11.130

8.  WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.

Authors:  Man Wu; Xueqing Xia; Jiemiao Hu; Natalie Wall Fowlkes; Shulin Li
Journal:  Nat Commun       Date:  2021-06-09       Impact factor: 14.919

9.  Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics.

Authors:  Kelly Street; Davide Risso; Russell B Fletcher; Diya Das; John Ngai; Nir Yosef; Elizabeth Purdom; Sandrine Dudoit
Journal:  BMC Genomics       Date:  2018-06-19       Impact factor: 3.969

10.  IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection.

Authors:  Pawan Kumar; Kamalakannan Rajasekaran; Arash Nanbakhsh; Jack Gorski; Monica S Thakar; Subramaniam Malarkannan
Journal:  Sci Rep       Date:  2019-03-21       Impact factor: 4.379

View more
  1 in total

Review 1.  Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle.

Authors:  Francesca Salani; Virginia Genovesi; Caterina Vivaldi; Valentina Massa; Silvia Cesario; Laura Bernardini; Miriam Caccese; Jessica Graziani; Dario Berra; Lorenzo Fornaro; Gianluca Masi
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.